Psilocybin is under clinical development by Tryptamine Therapeutics and currently in Phase II for Irritable Bowel Syndrome. According to GlobalData, Phase II drugs for Irritable Bowel Syndrome have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Psilocybin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Psilocybin overview
Psilocybin (TRP-8802) is under development for the treatment of fibromyalgia, binge eating disorder, irritable bowel syndrome (IBS), hypothalamic obesity and chronic pain conditions. It is administered orally as a capsule and also administered intravenously. It is a psychedelic drug.
Tryptamine Therapeutics overview
Tryptamine Therapeutics formerly Exopharm is a biopharmaceutical company that involves in advancing Genetic Medicines and other exosome-based medicines using exosomes or extracellular vesicles (EVs) as a chassis for improved and non-viral drug delivery. The Company invests in biopharmaceutical drug development. The company evaluates engineered EVs to transfer drugs, proteins and nucleic acids into specific cells. Exopharm utilizes LEAP proprietary technology platform for purification and production of EVs; LOAD and EVPS technology for designing and manufacturing engineered EVs. It seeks to work in partnership with biopharmaceutical companies to design exosome based therapies. Tryptamine is headquartered in Camberwell, Victoria, Australia.
For a complete picture of Psilocybin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
